Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

Mes dernières consult.
Most popular
Analysis summary4-Traders Strategies

David Meurisse

Contributor / Partner
share with twitter share with LinkedIn share with facebook
share via e-mail

Expectation of a turn-around

Strategy published on 12/30/2016 | 14:47
long trade
Target price hit
Entry price : 147.63$ | Target : 157.4$ | Stop-loss : 143.9$ | Potential : 6.62%
The technical chart pattern of Amgen, Inc. shares shows signs of a reversal that argue in favor of a return to a positive outlook over the medium term.
Investors have an opportunity to buy the stock and target the $ 157.4.
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Historically, the company has been releasing figures that are above expectations.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • Based on current prices, the company has particularly high valuation levels.
  • Below the resistance at 153.21 USD, the stock shows a negative configuration when looking looking at the weekly chart.
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2018 22 585 M
EBIT 2018 11 440 M
Net income 2018 8 234 M
Finance 2018 6 263 M
Yield 2018 2,81%
P/E ratio 2018 15,32
P/E ratio 2019 14,11
EV / Sales 2018 5,52x
EV / Sales 2019 5,34x
Capitalization 131 B
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Duration : Period : Week
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders